Recent developments

at Tullis and our portfolio companies

News

Keeping you current on new and follow-on investments, portfolio product and service milestones, publications and events, management and board transitions, and other developments in Tullis funds.

December

26

electroCore Expands Intellectual Property Portfolio

electroCore Granted Two New U.S. Patents ROCKAWAY, N.J., Dec. 26, 2023 (GLOBE NEWSWIRE) — electroCore, Inc....

14

TriSalus Life Sciences Announces CMS Reimbursement for the TriNav® Infusion System via Assignment of a New Technology Healthcare Common Procedure Coding System (HCPCS) Code

DENVER–(BUSINESS WIRE)–TriSalus Life Sciences® Inc., (Nasdaq: TLSI), an oncology company integrating its novel delivery technology...

12

electroCore Expands Intellectual Property Portfolio for Nerve Stimulation Technology

ROCKAWAY, N.J., Dec. 12, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine...

14

TriSalus Reports Third Quarter 2023 Financial Results and Provides Business Update

Completed merger with MedTech Acquisition Corporation (MTAC) and started public trading August 11th Reported 3Q23 revenues of $5.2...

13

Exagen Inc. Reports Strong Third Quarter 2023 Results

SAN DIEGO, California, Nov. 13, 2023 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune...

9

Exagen Inc. and Johns Hopkins University Announce License Agreement for Novel Patented Lupus Nephritis Biomarkers

SAN DIEGO, California, Nov. 09, 2023 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune...

8

electroCore Announces Third Quarter 2023 Financial Results

Record third quarter 2023 net sales of $4.5 million, an increase of approximately 128% over third quarter...

7

TriSalus Life Sciences to Host Third Quarter 2023 Financial Results Conference Call

Call Scheduled for Tuesday, November 14, 2023, at 9:00 a.m. ET DENVER–(BUSINESS WIRE)–Nov. 7, 2023– TriSalus Life...

6

ATEC Reports Third Quarter 2023 Financial Results and Raises Full Year 2023 Adjusted EBITDA Guidance

CARLSBAD, Calif.–(BUSINESS WIRE)– Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to...

4

Late-Breaking Phase 1 Liver Metastasis Data from TriSalus Presented at SITC 2023 Supports Development of Innovative Immuno-oncology Approach for Liver and Pancreas Indications

New data from PERIO-01 clinical trial indicates PEDD™ method resulted in modulation of the...

3

TriSalus Life Sciences Presents Data for SD-101 Delivered by TriSalus Infusion System for Pancreatic Adenocarcinoma at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

New data from PERIO-03 clinical trial indicates PEDD™ method resulted in modulation of the...

31

ATEC Equipped to Support Ramping Surgical Volume With Proceeds From Secondary Offering

Positioned to invest in revenue-generating assets as Company continues to capitalize on industry disruptions...

Recent developments

December

26

electroCore Expands Intellectual Property Portfolio

December

14

TriSalus Life Sciences Announces CMS Reimbursement for the TriNav® Infusion System via Assignment of a New Technology Healthcare Common Procedure Coding System (HCPCS) Code

December

12

electroCore Expands Intellectual Property Portfolio for Nerve Stimulation Technology

November

14

TriSalus Reports Third Quarter 2023 Financial Results and Provides Business Update

November

13

Exagen Inc. Reports Strong Third Quarter 2023 Results

November

9

Exagen Inc. and Johns Hopkins University Announce License Agreement for Novel Patented Lupus Nephritis Biomarkers

November

8

electroCore Announces Third Quarter 2023 Financial Results

November

7

TriSalus Life Sciences to Host Third Quarter 2023 Financial Results Conference Call

November

6

ATEC Reports Third Quarter 2023 Financial Results and Raises Full Year 2023 Adjusted EBITDA Guidance

November

4

Late-Breaking Phase 1 Liver Metastasis Data from TriSalus Presented at SITC 2023 Supports Development of Innovative Immuno-oncology Approach for Liver and Pancreas Indications

November

3

TriSalus Life Sciences Presents Data for SD-101 Delivered by TriSalus Infusion System for Pancreatic Adenocarcinoma at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

October

31

ATEC Equipped to Support Ramping Surgical Volume With Proceeds From Secondary Offering